Catherine Slaugh, NP
Primary Care · Wilmington, DENPI 1871251595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$343
- Novartis$340
- Merck$320
- Boehringer Ingelheim$317
- Johnson & Johnson$198
- E.r. Squibb & Sons, L.L.C.$195
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 15 | $343 |
| Novartis | 17 | $340 |
| Merck | 16 | $320 |
| Boehringer Ingelheim | 12 | $317 |
| Johnson & Johnson | 10 | $198 |
| E.r. Squibb & Sons, L.L.C. | 11 | $195 |
| Novo Nordisk | 9 | $184 |
| Atricure, Inc. | 6 | $161 |
| Amarin Pharma, Inc. | 9 | $157 |
| Pfizer | 7 | $137 |
| Esperion Therapeutics, Inc. | 7 | $122 |
| AstraZeneca | 4 | $110 |
| Daiichi Sankyo Inc. | 5 | $107 |
| Scpharmaceuticals Inc. | 4 | $93 |
| Amgen | 5 | $83 |
| Baxter Healthcare | 2 | $81 |
| Boston Scientific | 3 | $72 |
| Philips North America LLC | 3 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Tactile Systems Technology Inc | 3 | $55 |
| Lilly USA, LLC | 2 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $52 |
| Exact Sciences | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Medtronic | 1 | $27 |
| Biotronik Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Edwards Lifesciences | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $14 |
How this compares
$3,571 in reported general payments places this provider in the 95th percentile of 25 primary care providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $42,203 |
| XareltoRivaroxaban | 12 | $15,493 |
| OzempicSemaglutide | 14 | $14,687 |
| Rosuvastatin Calcium | 43 | $917 |
| Atorvastatin Calcium | 49 | $876 |
| Olmesartan Medoxomil | 26 | $599 |
| Ezetimibe | 14 | $570 |
| Metoprolol Succinate | 23 | $569 |
| Amlodipine Besylate | 53 | $419 |
| Amiodarone Hcl | 17 | $301 |
| Lisinopril | 19 | $202 |
| Losartan Potassium | 11 | $190 |
| Hydrochlorothiazide | 32 | $173 |
| Carvedilol | 26 | $149 |
| Metformin Hcl | 16 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $137 | $42,20337 claims |
| Johnson & JohnsonXarelto | $198 | $15,49312 claims |
| Novo NordiskOzempic | $184 | $14,68714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 primary care providers in Delaware.
Other primary care in Wilmington
- Florence AkouegnonWilmington$5K
- Cynthia Lang-GroeningWilmington$3K
- Julie MbuaWilmington$1K
- Christina RiceWilmington$618
- Lydia AkomeahWilmington$339
- Sharon MinerWilmington$217
- Ariel MooreWilmington$120
- Lisa SugarWilmington$24
- Hardi PatelDover$3K
- Rachael OfiliNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.